A detailed history of Wells Fargo & Company transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 115,017 shares of RXRX stock, worth $655,596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,017
Previous 77,215 48.96%
Holding current value
$655,596
Previous $579,000 30.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.92 - $8.6 $223,787 - $325,097
37,802 Added 48.96%
115,017 $757,000
Q2 2024

Aug 13, 2024

BUY
$7.35 - $10.05 $137,430 - $187,914
18,698 Added 31.95%
77,215 $579,000
Q1 2024

May 10, 2024

BUY
$9.13 - $15.52 $59,774 - $101,609
6,547 Added 12.6%
58,517 $583,000
Q4 2023

Feb 09, 2024

SELL
$5.09 - $10.79 $981,932 - $2.08 Million
-192,914 Reduced 78.78%
51,970 $512,000
Q3 2023

Nov 13, 2023

BUY
$6.59 - $15.86 $867,323 - $2.09 Million
131,612 Added 116.19%
244,884 $1.87 Million
Q2 2023

Aug 15, 2023

BUY
$4.56 - $9.94 $112,376 - $244,961
24,644 Added 27.81%
113,272 $846,000
Q1 2023

May 12, 2023

BUY
$6.42 - $9.64 $555,991 - $834,852
86,603 Added 4276.69%
88,628 $591,000
Q4 2022

Feb 13, 2023

BUY
$7.16 - $12.7 $2,155 - $3,822
301 Added 17.46%
2,025 $15,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $2,646 - $4,596
338 Added 24.39%
1,724 $19,000
Q2 2022

Aug 12, 2022

SELL
$5.04 - $9.26 $43,636 - $80,173
-8,658 Reduced 86.2%
1,386 $12,000
Q1 2022

May 16, 2022

SELL
$6.16 - $18.03 $250,102 - $732,036
-40,601 Reduced 80.17%
10,044 $71,000
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $817,200 - $1.11 Million
50,632 Added 389476.91%
50,645 $868,000
Q3 2021

Nov 15, 2021

BUY
$19.03 - $41.33 $247 - $537
13 New
13 $0

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.03B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.